Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 3/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909624 | 0.96 | KDM4E (0.47) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL15171151 | 0.94 | LSS (0.40) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14575794 | 0.85 | KDM4E (0.46) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14575792 | 0.85 | KDM4E (0.46) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL14576547 | 0.83 | KDM4E (0.45) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL15135714 | 0.83 | KDM4E (0.41) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL18909625 | 0.83 | KDM4E (0.41) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL14576545 | 0.83 | KDM4E (0.45) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL30719696 | 0.83 | KDM4E (0.41) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14706379 | 0.83 | KDM4E (0.41) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968205-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | KDM4E 1554/4885HTR2A 3682/4885HTR2C 1365/4885 |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | KDM4E 255/4885HTR2A 3926/4885HTR2C 3942/4885 |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | KDM4E 1554/4885HTR2A 3682/4885HTR2C 1365/4885 |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | KDM4E 1554/4885HTR2A 3682/4885HTR2C 1365/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | KDM4E 255/4885HTR2A 3926/4885HTR2C 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.